SCHEMBL13664001

SCHEMBL13664001

Nc1ccn([C@@H]2C=C(CO)[C@H](O)C2)c(=O)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
THRB P10828 1/20 0.50
MTOR P42345 1/20 0.50
MDM2 Q00987 1/20 0.50
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
PDE3A Q14432 3/20 0.45
CACNA1F O60840 2/20 0.45
ALB P02768 2/20 0.45
MAPT P10636 2/20 0.45
CACNA1D Q01668 2/20 0.45
CACNA1S Q13698 2/20 0.45
CACNA1C Q13936 2/20 0.45
PDE4D Q08499 1/20 0.44
SLC29A1 Q99808 1/20 0.44
NT5E P21589 1/20 0.39
POLB P06746 1/20 0.39
FGFR1 P11362 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
POLG P54098 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10494028 1.00 LMNA (0.50) LMNATHRBMTORMDM2NCOA1
SCHEMBL19052788 0.81 PDE3A (0.43) LMNATHRBMTORMDM2NCOA1
SCHEMBL19052854 0.81 PDE3A (0.43) LMNATHRBMTORMDM2NCOA1
SCHEMBL18573820 0.75 CDA (0.60) LMNATHRBMTORMDM2NCOA1
SCHEMBL14946375 0.75 CDA (0.60) LMNATHRBMTORMDM2NCOA1
SCHEMBL10392960 0.75 CDA (0.60) LMNATHRBMTORMDM2NCOA1
SCHEMBL14853915 0.75 CDA (0.60) LMNATHRBMTORMDM2NCOA1
SCHEMBL10383196 0.75 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL13667654 0.75 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL8662563 0.73 LMNA (0.46) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270431-A1 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) 2009-10-29 US disclosed
WO-2007047793-A2 CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270431-A1 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections REV1, NSUN2, ORC3 LMNA 954/4885THRB 1833/4885MTOR 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.